Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
19 August 2021 | Story André Damons | Photo Charl Devenish
Ebeth Grobbelaar is a Scientific Manager in the South African Doping Control Laboratory (SADoCoL) who is responsible for the review and approval of results at SADoCoL, to ensure compliance with the technical requirements of the World Anti-Doping Agency (WADA).

For Ebeth Grobbelaar, Scientific Manager in the South African Doping Control Laboratory (SADoCoL) – which is housed by the University of the Free State (UFS) – her work at the laboratory is profound, as fairness on and off the playing field is vital to her.

“Creating a fair playing field for athletes to compete carries a heavy responsibility, as an anti-doping violation impacts the athlete’s career,” says Grobbelaar, who is responsible for the review and approval of results at SADoCoL to ensure compliance with the technical requirements of the World Anti-Doping Agency (WADA).

Women are the cogs in the wheel

According to her, anabolic steroids, the multiple analytical disciplines, and rapidly changing technical requirements from WADA have attracted her to the sciences of anti-doping. Sixty percent of her colleagues at SADoCoL are women.  “They are the cogs in the wheel, ensuring the laboratory's smooth operation, taking daily challenges in their stride, and excelling in what they do as analysts and administrative staff,” says Grobbelaar.

Grobbelaar says there are many options in the anti-doping field for women inside and outside of the laboratory. Some of the most influential people in the anti-doping community are women – in their roles as laboratory directors, leading researchers, directors of athlete passport management units for international sports federations, or national anti-doping agencies in various capacities.

With all the responsibilities, come challenges and pressure – especially in a year when the Olympic Games take place. 

Women should learn how to say ‘no’ 

“An Olympic year always has additional stress due to the large number of samples before the games. This year, the pressure is more, with not all accredited laboratories operational, as well as disrupted testing schedules due to COVID-19.  Enabling athletes to compete in fairness on the world stage is a responsibility and a privilege.”

“My faith is my anchor.  As far as possible, I try to leave my work behind when I leave the laboratory, and concentrate on enjoyable things such as gardening, my dog, reading, and walking with my dog. On challenging days, something sweet also helps,” explains Grobbelaar the pressure and how she copes with it. 

This Women’s Month, Grobbelaar says, women should learn how to say ‘no’ to create time for rest and play. Says Grobbelaar: “For many women, ‘doing your best’ or saying yes means working yourself to the point of a mental and physical breakdown. Having the courage to say no, loving oneself through rest and play, replenishing our spirits, and realising that we are unique and precious in God’s eyes, is a challenge that many women face.” 

“Rest and play can take different forms, such as having coffee with a friend or being creative.  The important thing is that your rest or play activity brings joy to your soul and energises you. Ask your friends to support and assist you,” she concludes. 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept